Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Given Consensus Rating of “Moderate Buy” by Brokerages

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) has been assigned an average rating of “Moderate Buy” from the twelve analysts that are presently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, ten have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $10.30.

A number of equities analysts recently issued reports on TSHA shares. Wells Fargo & Company raised their target price on Taysha Gene Therapies from $7.50 to $8.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 13th. Chardan Capital reissued a “buy” rating and issued a $12.00 price objective on shares of Taysha Gene Therapies in a report on Wednesday, November 5th. Raymond James Financial started coverage on Taysha Gene Therapies in a research note on Tuesday, October 21st. They issued a “strong-buy” rating and a $13.00 price objective for the company. Robert W. Baird lifted their target price on Taysha Gene Therapies from $7.00 to $12.00 and gave the stock an “outperform” rating in a report on Thursday, October 2nd. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $10.00 price target on shares of Taysha Gene Therapies in a report on Friday, October 17th.

Insider Buying and Selling at Taysha Gene Therapies

In other news, insider Sukumar Nagendran sold 200,000 shares of the stock in a transaction on Wednesday, September 10th. The shares were sold at an average price of $3.23, for a total value of $646,000.00. Following the sale, the insider owned 1,006,439 shares in the company, valued at $3,250,797.97. This represents a 16.58% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 3.78% of the stock is owned by insiders.

Institutional Investors Weigh In On Taysha Gene Therapies

Hedge funds have recently added to or reduced their stakes in the business. ST Germain D J Co. Inc. grew its position in Taysha Gene Therapies by 81.8% during the 3rd quarter. ST Germain D J Co. Inc. now owns 9,633 shares of the company’s stock worth $32,000 after purchasing an additional 4,333 shares during the period. Arrowpoint Investment Partners Singapore Pte. Ltd. purchased a new stake in shares of Taysha Gene Therapies in the third quarter worth about $40,000. Marex Group plc acquired a new stake in Taysha Gene Therapies during the second quarter worth about $29,000. E Fund Management Co. Ltd. acquired a new stake in Taysha Gene Therapies during the second quarter worth about $31,000. Finally, Allegheny Financial Group purchased a new position in Taysha Gene Therapies during the third quarter valued at approximately $49,000. 77.70% of the stock is owned by hedge funds and other institutional investors.

Taysha Gene Therapies Stock Up 5.0%

Taysha Gene Therapies stock opened at $4.19 on Friday. Taysha Gene Therapies has a 1-year low of $1.05 and a 1-year high of $5.51. The business has a fifty day moving average price of $4.19 and a 200-day moving average price of $3.22. The company has a debt-to-equity ratio of 0.23, a current ratio of 10.48 and a quick ratio of 10.48. The stock has a market capitalization of $1.15 billion, a price-to-earnings ratio of -12.70 and a beta of 1.00.

Taysha Gene Therapies (NASDAQ:TSHA) last released its quarterly earnings results on Tuesday, November 4th. The company reported ($0.09) EPS for the quarter, meeting analysts’ consensus estimates of ($0.09). Taysha Gene Therapies had a negative return on equity of 67.26% and a negative net margin of 1,144.97%. Equities research analysts forecast that Taysha Gene Therapies will post -0.35 EPS for the current fiscal year.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.